Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin and Neurophysiological Responses to Eye Gaze
NCT03272321Phase 2Completed
- Sponsor
- KU Leuven
- Start
- Jul 2017
- Primary completion
- May 2018
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin nasal spray in Autism Spectrum Disorder (ASD) (2 arms), sponsored by KU Leuven. Primary endpoints: Change in EEG asymmetry and Change in skin conductance response. Started Jul 2017; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03272321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03272321.